Nachrichten zur Cytomx Therapeutics Inc. Aktie

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in…

Form 8-K CytomX Therapeutics, For: Nov 16

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies....…

CytomX Therapeutics Shares Rally on Regeneron Pact

CytomX Therapeutics Shares Rally on Regeneron Pact...…

Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX

Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX...…

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do…

CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

- Advancing wholly owned, next-generation conditionally activated therapeuticsCX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 -...…

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is…

CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in…

dpa-AFX ProFeed